View in EDS HTML Full Text PDF Full Text

Phase I study of pembrolizumab in combination with ibrutinib for the treatment of unresectable or metastatic melanoma.

Saved in:
Bibliographic Details
Title: Phase I study of pembrolizumab in combination with ibrutinib for the treatment of unresectable or metastatic melanoma.
Authors: Yao Y; Department of Oncology, Mayo Clinic, Rochester, MN, United States., Yan Y; Division of Hematology and Oncology, Department of Medicine, Mayo Clinic, Jacksonville, FL, United States., Suman VJ; Department of Health Sciences, Division of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, United States., Dietz AB; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States., Erskine CL; Department of Immunology, Mayo Clinic, Rochester, MN, United States., Dimou A; Department of Oncology, Mayo Clinic, Rochester, MN, United States., Markovic SN; Department of Oncology, Mayo Clinic, Rochester, MN, United States.; Department of Immunology, Mayo Clinic, Rochester, MN, United States., McWilliams RR; Department of Oncology, Mayo Clinic, Rochester, MN, United States., Montane HN; Department of Oncology, Mayo Clinic, Rochester, MN, United States., Block MS; Department of Oncology, Mayo Clinic, Rochester, MN, United States.; Department of Immunology, Mayo Clinic, Rochester, MN, United States.
Source: Frontiers in immunology [Front Immunol] 2025 Feb 04; Vol. 16, pp. 1491448. Date of Electronic Publication: 2025 Feb 04 (Print Publication: 2025).
Publication Type: Journal Article; Clinical Trial, Phase I
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39967670
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase I study of pembrolizumab in combination with ibrutinib for the treatment of unresectable or metastatic melanoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Yao+Y%22">Yao Y</searchLink>; Department of Oncology, Mayo Clinic, Rochester, MN, United States.<br /><searchLink fieldCode="AU" term="%22Yan+Y%22">Yan Y</searchLink>; Division of Hematology and Oncology, Department of Medicine, Mayo Clinic, Jacksonville, FL, United States.<br /><searchLink fieldCode="AU" term="%22Suman+VJ%22">Suman VJ</searchLink>; Department of Health Sciences, Division of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, United States.<br /><searchLink fieldCode="AU" term="%22Dietz+AB%22">Dietz AB</searchLink>; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States.<br /><searchLink fieldCode="AU" term="%22Erskine+CL%22">Erskine CL</searchLink>; Department of Immunology, Mayo Clinic, Rochester, MN, United States.<br /><searchLink fieldCode="AU" term="%22Dimou+A%22">Dimou A</searchLink>; Department of Oncology, Mayo Clinic, Rochester, MN, United States.<br /><searchLink fieldCode="AU" term="%22Markovic+SN%22">Markovic SN</searchLink>; Department of Oncology, Mayo Clinic, Rochester, MN, United States.; Department of Immunology, Mayo Clinic, Rochester, MN, United States.<br /><searchLink fieldCode="AU" term="%22McWilliams+RR%22">McWilliams RR</searchLink>; Department of Oncology, Mayo Clinic, Rochester, MN, United States.<br /><searchLink fieldCode="AU" term="%22Montane+HN%22">Montane HN</searchLink>; Department of Oncology, Mayo Clinic, Rochester, MN, United States.<br /><searchLink fieldCode="AU" term="%22Block+MS%22">Block MS</searchLink>; Department of Oncology, Mayo Clinic, Rochester, MN, United States.; Department of Immunology, Mayo Clinic, Rochester, MN, United States.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101560960%22">Frontiers in immunology</searchLink> [Front Immunol] 2025 Feb 04; Vol. 16, pp. 1491448. <i>Date of Electronic Publication: </i>2025 Feb 04 (<i>Print Publication: </i>2025).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase I
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101560960 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>1664-3224 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216643224%22">16643224 </searchLink><i>NLM ISO Abbreviation: </i>Front Immunol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39967670
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fimmu.2025.1491448
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1491448
    Titles:
      – TitleFull: Phase I study of pembrolizumab in combination with ibrutinib for the treatment of unresectable or metastatic melanoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Yao Y
      – PersonEntity:
          Name:
            NameFull: Yan Y
      – PersonEntity:
          Name:
            NameFull: Suman VJ
      – PersonEntity:
          Name:
            NameFull: Dietz AB
      – PersonEntity:
          Name:
            NameFull: Erskine CL
      – PersonEntity:
          Name:
            NameFull: Dimou A
      – PersonEntity:
          Name:
            NameFull: Markovic SN
      – PersonEntity:
          Name:
            NameFull: McWilliams RR
      – PersonEntity:
          Name:
            NameFull: Montane HN
      – PersonEntity:
          Name:
            NameFull: Block MS
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 04
              M: 02
              Text: 2025 Feb 04
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1664-3224
          Numbering:
            – Type: volume
              Value: 16
          Titles:
            – TitleFull: Frontiers in immunology
              Type: main
ResultId 1